Cargando…

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA

BACKGROUND: Nicotine use is higher among patients with schizophrenia (50–98%) than in general population (25–30%). This association can reflect a non-specific liability to substance use or specific effects of tobacco on symptoms severity or side effects. Studies about nicotine use and schizophrenia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliveira, Hianna, Coutinho, Luccas, Higuchi, Cinthia, Noto, Cristiano, Bressan, Rodrigo, Gadelha, Ary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888281/ http://dx.doi.org/10.1093/schbul/sby016.376

Ejemplares similares

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

F91. ASSOCIATION BETWEEN SYMPTOM DIMENSIONS AND EXECUTIVE FUNCTION IN SCHIZOPHRENIA
por: Franco, Ana Luiza, et al.
Publicado: (2018)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
por: Malinowski, Fernando R., et al.
Publicado: (2019)

What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review
por: Haguiara, Bernardo, et al.
Publicado: (2021)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey
por: Costardi, Carlos Gustavo, et al.
Publicado: (2022)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

T126. PSYCHOTIC EXPERIENCES AND COMMON MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE: BIDIRECTIONAL AND TRANSDIAGNOSTIC ASSOCIATIONS IN A LONGITUDINAL COMMUNITY-BASED STUDY
por: Pan, Pedro, et al.
Publicado: (2018)

O12.8. LOWER FAMILY INCOME PREDICTS PSYCHOTIC EXPERIENCES IN A COMMUNITY SAMPLE OF YOUTHS IN BRAZIL: RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
por: Fonseca, Lais, et al.
Publicado: (2018)

Predictive biomarkers for negative symptoms in schizophrenia
por: Cakici, N., et al.
Publicado: (2021)

Marker of schizophrenia with enduring negative symptoms
por: Dmitrieva, E., et al.
Publicado: (2022)

A case report of inhibition and severe desnutrition: negative symptoms in resistant schizophrenia
por: Coucheiro Limeres, P., et al.
Publicado: (2022)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
por: Nani, João V, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

S24. PATHWAYS LINKING ENVIRONMENTAL RISKS, POLYGENIC RISK SCORE TO SCHIZOPHRENIA AND PSYCHOTIC EXPERIENCES IN A BRAZILIAN COHORT OF CHILDREN AND ADOLESCENTS
por: Fonseca, Lais, et al.
Publicado: (2020)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Negative and Cognitive Symptoms of Schizophrenia: Are there Adequate Pharmacological Treatments?
por: Vasiliu, O.
Publicado: (2022)

Negative symptoms and associated factors in older people with schizophrenia
por: Karoui, M., et al.
Publicado: (2023)

F168. PSYCHOTIC EXPERIENCE AND ADOLESCENT BRAIN TRAJECTORY: EVIDENCE FOR STRUCTURAL ALTERATIONS IN DOPAMINERGIC REGIONS
por: Zugman, Andre, et al.
Publicado: (2018)

The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in subjects with schizophrenia
por: Caporusso, E., et al.
Publicado: (2023)

100 years of recovery and prognosis in schizophrenia
por: Molstrom, I.-M., et al.
Publicado: (2023)

Negative symptoms of schizophrenia in patients with acute and transient psychotic disorders
por: Aleshkina, G., et al.
Publicado: (2021)

Therapeutic effect of qinghuanling on negative symptoms and cognitive function of schizophrenia
por: Zhang, Y., et al.
Publicado: (2021)

Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes
por: Berberian, Arthur A., et al.
Publicado: (2018)

T46. TARGETING THE IMMUNE SYSTEM TO TREAT DEPRESSION AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Krynicki, Carl, et al.
Publicado: (2018)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

T125. INCIDENCE OF TREATMENT RESISTANCE SCHIZOPHRENIA IN A COMMUNITY SAMPLE USING THE TRRIP CONCENSUS
por: Joyce, Dan, et al.
Publicado: (2018)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

PM521. Relationship between Negative Symptoms and Social Cognition in Patient with Schizophrenia
por: Hyun, Jiewon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ub2nhr1e9aavrsbbrmk23faos2